MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor
Sign Up to like & getrecommendations! Published in 2024 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-24-1750
Abstract: Abstract Purpose: Malignant peripheral nerve sheath tumor (MPNST) is a highly aggressive subtype of soft-tissue sarcoma with a high propensity to metastasize and extremely limited treatment options. Loss of the RAS-GAP NF1 leads to sustained… read more here.
Keywords: combination; dimer inhibitors; raf dimer; mek ... See more keywords
Abstract 6415: RAF dimer inhibitor lifirafenib enhances the antitumor activity of MEK inhibitor mirdametinib in RAS mutant tumors
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.am2020-6415
Abstract: K-RAS mutation represents one of the most frequent genetic alterations in cancers. Monotherapy approaches targeting RAS downstream effectors such as MEK and ERK have had limited clinical success in patients with K-RAS-mutated cancers. The reduced… read more here.
Keywords: inhibitor; mek inhibitor; raf dimer; dimer inhibitor ... See more keywords
ARAF Mutations Limit Response to RAF Dimer Inhibition.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-rw2021-069
Abstract: Belvarafenib is active in BRAF- and NRAS-mutant tumors, but acquired ARAF mutations drive resistance. read more here.
Keywords: mutations limit; limit response; raf dimer; araf mutations ... See more keywords